Skip to main content

Simon Schwartz Navarro

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Simon Schwartz Navarro

Institutions of which they are part

Main researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca
Cap de Secció
Bioquímica
Cross-departmental services

Senior scientist and advisor with specific interest in Nanomedicine and Advanced Therapies applied to unmet clinical needs. I am also acting as strategy coordinator to facilitate programs and initiatives that foster innovation in new treatments and diagnostic tools.

Senior research of the clinical biochemistry - drug delivery and therapy group at VHIR and Strategy director of biobanking and biomodels at Vall d'hebron Campus. President of the European Society of Nanomedicine and Executive Board member of the International Society of Nanomedicine. Former director general of the Blood and Tissue Banc of Catalonia. Former director of CIBBIM-Nanomedicine. Former scientific associate director of CIBER-BBN and coordinator of technology transfer. Former director assistance of translational research at VHIR. H-index of 48, with more that 120 high impact publications, 19 transferred patents and several EU granted projects. Co-founder of 3 biotech companies (i.e, Bsure Medical ltd). Science Advisor of the European Nanomedicine Characterization Laboratory (EU-NCL). Member of the editorial Board of Precision Nanomedicine, J. Nanotechnology and of J. of Nanotheranostics. Former editorial Board member of Eur. J. Nanomedicine and Nanomedicine-NBM. Exper member of the nanomedicine group at EMA.

Projects

HydroTheC

IP: -
Collaborators: Miriam Izquierdo Sans, Diana Fernandes de Rafael, Simon Schwartz Navarro
Funding agency: EUROPEAN COMMISSION
Funding: 221390.88
Reference: HYDROTEC_HE-MSCA-PF-GF2022
Duration: 01/01/2024 - 31/12/2026

MIMIC-KeY - A KEY TO THE RATIONAL DESIGN OF EXTRACELLULAR VESICLES-MIMICKING NANOPARTICLES.

IP: Simon Schwartz Navarro
Collaborators: Joaquin Seras Franzoso, Julia German Cortes, Zamira Vanessa Diaz Riascos
Funding agency: EUROPEAN COMMISSION
Funding: 457250
Reference: MIMIC-KEY_H2020-FETPROACT-2020
Duration: 01/06/2021 - 30/11/2025

Tumor-derived extracellular vesicles as protein delivery carriers to modulate cancer stem cell dynamic phenotype and metastatic niche-conditioning through cellular inter-communication.

IP: -
Collaborators: Joaquin Seras Franzoso, Simon Schwartz Navarro
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI20/01474
Duration: 01/01/2021 - 05/04/2021

ACTUALIZACIÓN DE EQUIPAMIENTOS DE ALTA TECNOLOGIA PARA LA PLATAFORMA DE IMAGEN PRECLINICA. ADQUISICION DE UN EQUIPO DE ULTRASONIDOS DE INVESTIGACION PRECLINICA

IP: Inmaculada Fuentes Camps
Collaborators: César Serrano Garcia, Anna Meseguer Navarro, Josep Tabernero Caturla, Antonio Rodríguez Sinovas, Francesc Bosch Albareda, Victor Franco Puntes, José Raul Herance Camacho, Jordi Giralt López de Sagred, Màrius Aguirre Canyadell, Xavier Serres Créixams, Simon Schwartz Navarro, Eva Muñoz Couselo, Joaquim Mateo Valderrama, Mario Marotta Baleriola, Anna Rosell Novel, Joan Genescà Ferrer
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 108390
Reference: EQC2019-006322-P
Duration: 01/01/2019 - 31/12/2020

Ministerio de Ciencia

Related news

The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.

The new system, made of cellulose and chitosan, enables sustained release of docetaxel and has demonstrated antitumor activity in preclinical models of ovarian cancer and glioblastoma.

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

Related professionals

Yuri Lara Taranchenko

Yuri Lara Taranchenko

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Sara García Hidalgo

Sara García Hidalgo

Predoctoral researcher
Ophtalmology
Read more
Anna Jeanne Behr

Anna Jeanne Behr

Predoctoral researcher
Gene Therapy at Nervous System
Read more
Andrea Pérez Manrique

Andrea Pérez Manrique

Research technician
Basic, Translational and Clinical Pharmacy Research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.